中医扶正散结法干预非霍奇金淋巴瘤治疗的临床研究  

Clinical study on intervention of traditional Chinese Medicine in the treatment of Non-Hodgkin’s Lymphoma

作　　者：于洁[1] 李薇薇[1] 夏征[1] 徐羽[1] 姬卫国[1] 王俊涛[1] 贾润霞[1] 王祥麒[1] YU Jie;LI Wei-wei;XIA Zheng;XU Yu;JI Wei-guo;WANG Jun-tao;JIA Run-xia;WANG Xiang-qi(Department of Oncology,The Third Afiliated Hospital of Henan University of Traditional Chinese Medieine,ZhengzhouHenan 45000)

机构地区：[1]河南中医药大学第三附属医院肿瘤科,河南郑州450000

出　　处：《世界中西医结合杂志》2021年第5期936-940,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：河南省中医药科学研究专项课题(2017ZY2028);河南省中医药科学研究专项课题(2019ZY2153)。

摘　　要：目的观察分析中医扶正散结法干预非霍奇金淋巴瘤治疗的临床效果。方法选取2015年3月—2017年7月期间在河南中医药大学第三附属医院肿瘤科接受治疗的非霍奇金淋巴瘤患者124例,按随机数字表法将患者分成治疗组62例,对照组62例。对照组患者采用CHOP方案进行化疗,治疗组在对照组基础上,给予扶正散结汤进行治疗。观察两组临床疗效、T细胞亚群情况、治疗毒副作用、生活质量改善情况和生存期情况。结果治疗后治疗组患者缓解率80.65%(50/62)明显高于对照组62.90%(39/62),差异有统计学意义(χ^(2)=8.28,P<0.05)。治疗后对照组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)与治疗前比较明显降低(P<0.05);治疗后治疗组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)与治疗前比较明显增高(P<0.05),CD8^(+)与治疗前比较明显降低(P<0.05);且治疗后治疗组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)明显高于对照组(P<0.05),CD8^(+)明显低于对照组(P<0.05)。治疗过程中治疗组患者恶心呕吐、血小板降低、周围神经症状等毒副作用发生率明显低于对照组(P<0.05)。治疗后治疗组患者食欲改善、盗汗及睡眠改善、(Karnofsky)KPS评分增加、体重增加情况明显优于对照组(P<0.05)。治疗后对照组患者生存期范围为4~17个月,平均生存期(8.28±2.03)个月;治疗组患者生存期范围为5~24个月,平均生存期(12.93±3.76)个月,治疗组患者平均生存期明显优于对照组(t=6.89,P<0.05)。结论中医扶正散结法干预非霍奇金淋巴瘤治疗,具有较好的治疗效果,可明显改善患者机体免疫功能和生活质量,缓解化疗不良反应,延长生存期。该方法具有较高临床应用价值,值得推广。Objective To observe and analyze the clinical effect of Traditional Chinese Medicine(TCM)in treating non-Hodgkin’s lymphoma.Methods A total of 124 non-Hodgkin lymphoma patients who were treated in the Oncology Department of the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from March 2015 to July 2017 were selected.According to the random number table method,the patients were divided into treatment group 62 cases and control group 62 cases.example.The patients in the control group were treated with CHOP regimen,while the patients in the observation group were treated with Fuzheng Sanjie Decoction on the basis of the control group.T cell subsets,side effects,improvement of quality of life and survival time were observed in the two groups.Results After treatment,the remission rate of patients in the treatment group was 80.65%(50/62)significantly higher than 62.90%(39/62)in the control group,and the difference was statistically significant(χ^(2)=8.28,P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the control group were significantly lower than before treatment(P<0.05);after treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the treatment group were significantly higher than before treatment(P<0.05),and CD8^(+)was significantly higher than before treatment.It was significantly lower before treatment(P<0.05);and after treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the treatment group were significantly higher than those in the control group(P<0.05),and CD8^(+)was significantly lower than the control group(P<0.05).During the course of treatment,the incidence of side effects such as nausea and vomiting,thrombocytopenia,and peripheral nerve symptoms in the treatment group was significantly lower than the control group(P<0.05).After treatment,patients in the treatment group improved appetite,night sweats and sleep,increased KPS score,and weight gain were significantly better than those in the control group(P<0.05).After treatment,patients in the control group had a survival period of 4-

关 键 词：非霍奇金淋巴瘤 扶正散结 

分 类 号：R733[医药卫生—肿瘤]